Brainstorm Cell Therapeutics Stock Price, News & Analysis (NASDAQ:BCLI)

$4.00 -0.13 (-3.15 %)
(As of 11/21/2017 02:54 AM ET)
Previous Close$4.13
Today's Range$4.00 - $4.10
52-Week Range$2.07 - $5.18
Volume83,700 shs
Average Volume136,961 shs
Market Capitalization$77.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:BCLI
  • CUSIP: N/A
  • Web: www.brainstorm-cell.com
Debt:
  • Current Ratio: 1.78%
  • Quick Ratio: 1.78%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.53 per share
  • Price / Book: 7.55
Profitability:
  • Trailing EPS: ($0.31)
  • Net Income: $-4,980,000.00
  • Return on Equity: -76.45%
  • Return on Assets: -59.84%
Misc:
  • Employees: 22
  • Outstanding Shares: 18,840,000
 

Frequently Asked Questions for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its earnings results on Tuesday, October, 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. During the same period last year, the business earned ($0.09) EPS. View Brainstorm Cell Therapeutics' Earnings History.

When will Brainstorm Cell Therapeutics make its next earnings announcement?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Brainstorm Cell Therapeutics.

Where is Brainstorm Cell Therapeutics' stock going? Where will Brainstorm Cell Therapeutics' stock price be in 2017?

1 brokerages have issued 1 year price targets for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Brainstorm Cell Therapeutics.

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:

  • Irit Arbel, Independent Chairman of the Board (Age 57)
  • Chaim Lebovits, President, Chief Executive Officer (Age 46)
  • Alla Patlis, Interim Chief Financial Officer (Age 31)
  • Ralph Kern, Chief Operating Officer and Chief Medical Officer (Age 60)
  • Uri Yablonka, Executive Vice President, Chief Business Officer, Director (Age 40)
  • Chen Schor CPA, Director (Age 44)
  • June S. Almenoff M.D. Ph.D., Independent Director (Age 60)
  • Arturo O. Araya, Independent Director (Age 47)
  • Mordechai Friedman, Independent Director (Age 64)
  • Alon Pinkas, Independent Director (Age 56)

How do I buy Brainstorm Cell Therapeutics stock?

Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $4.00.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $77.82 million. The biotechnology company earns $-4,980,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Brainstorm Cell Therapeutics employs 22 workers across the globe.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 3 University Plaza Drive, Suite 320, HACKENSACK, NJ 07601, United States. The biotechnology company can be reached via phone at +1-201-4880460 or via email at mrice@lifesciadvisors.com.


MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (125.00% upside)

Consensus Price Target History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Price Target History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Maxim GroupSet Price TargetBuy$9.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Earnings by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Earnings History by Quarter for Brainstorm Cell Therapeutics (NASDAQ BCLI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018        
10/17/2017Q3 2017($0.16)($0.13)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.10)($0.06)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.30)($0.10)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.07)($0.03)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.11)($0.09)ViewN/AView Earnings Details
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
3/10/2016Q415($0.15)($0.07)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.12)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 12.94%
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Institutional Ownership by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Irit ArbelDirectorBuy2,500$4.26$10,650.00View SEC Filing  
8/23/2017Uri YablonkaEVPBuy2,000$3.98$7,960.00View SEC Filing  
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Source:
DateHeadline
Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Announce -$0.09 Earnings Per ShareZacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Announce -$0.09 Earnings Per Share
www.americanbankingnews.com - November 13 at 7:30 PM
AEterna Zentaris (AEZS) & Brainstorm Cell Therapeutics (BCLI) Financial ReviewAEterna Zentaris (AEZS) & Brainstorm Cell Therapeutics (BCLI) Financial Review
www.americanbankingnews.com - October 28 at 3:04 AM
FDA Approves New Use For Soliris, HSTM In Good Health, BYSI Springs A Surprise - NasdaqFDA Approves New Use For Soliris, HSTM In Good Health, BYSI Springs A Surprise - Nasdaq
www.nasdaq.com - October 24 at 3:26 AM
BrainStorm Expands Its Patent Portfolio to Include a New US Patent ... - PR Newswire (press release)BrainStorm Expands Its Patent Portfolio to Include a New US Patent ... - PR Newswire (press release)
www.prnewswire.com - October 24 at 3:26 AM
BrainStorm nabs new patent covering NurOwn; shares ahead 4%BrainStorm nabs new patent covering NurOwn; shares ahead 4%
seekingalpha.com - October 23 at 5:22 PM
BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinsons Disease And ALSBrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS
finance.yahoo.com - October 23 at 5:22 PM
Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric OxideCorporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide
finance.yahoo.com - October 20 at 6:10 PM
Brainstorm Cell Therapeutics Inc. (BCLI) to Post FY2017 Earnings of ($0.37) Per Share, Zacks Investment Research ForecastsBrainstorm Cell Therapeutics Inc. (BCLI) to Post FY2017 Earnings of ($0.37) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - October 20 at 12:16 PM
BrainStorm Cell Therapeutics (BCLI) CEO Chaim Lebovits on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaBrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - October 17 at 10:20 PM
BrainStorm Cell Therapeutics reports Q3 resultsBrainStorm Cell Therapeutics reports Q3 results
seekingalpha.com - October 17 at 5:17 PM
BrainStorm Announces Third Quarter 2017 Financial ResultsBrainStorm Announces Third Quarter 2017 Financial Results
finance.yahoo.com - October 17 at 5:17 PM
BCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALSBCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALS
finance.yahoo.com - October 17 at 5:17 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Announces  Earnings Results, Beats Estimates By $0.03 EPSBrainstorm Cell Therapeutics Inc. (BCLI) Announces Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - October 17 at 8:46 AM
Brainstorm Cell Therapeutics Inc. (BCLI) Given a $9.00 Price Target at Maxim GroupBrainstorm Cell Therapeutics Inc. (BCLI) Given a $9.00 Price Target at Maxim Group
www.americanbankingnews.com - October 16 at 12:58 PM
BrainStorm enrolls first patients in advanced ALS stem cell trialBrainStorm enrolls first patients in advanced ALS stem cell trial
finance.yahoo.com - October 16 at 2:11 AM
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALSBrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS
finance.yahoo.com - October 16 at 2:11 AM
Brainstorm Cell Therapeutics Inc. (BCLI) Scheduled to Post Quarterly Earnings on TuesdayBrainstorm Cell Therapeutics Inc. (BCLI) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 10 at 2:16 AM
Reviewing Cara Therapeutics (CARA) and Brainstorm Cell Therapeutics (BCLI)Reviewing Cara Therapeutics (CARA) and Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - October 5 at 4:48 PM
Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Post -$0.10 Earnings Per ShareZacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (BCLI) to Post -$0.10 Earnings Per Share
www.americanbankingnews.com - October 5 at 9:22 AM
Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17
finance.yahoo.com - October 3 at 4:13 PM
Head-To-Head Survey: Quintiles IMS Holdings (Q) versus Brainstorm Cell Therapeutics (BCLI)Head-To-Head Survey: Quintiles IMS Holdings (Q) versus Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - October 1 at 4:34 AM
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by ... - PR Newswire (press release)BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by ... - PR Newswire (press release)
www.prnewswire.com - September 29 at 8:46 AM
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK CapitalBrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
finance.yahoo.com - September 27 at 7:39 PM
Brainstorm Cell Therapeutics (BCLI) vs. Palatin Technologies (PTN) Head to Head ReviewBrainstorm Cell Therapeutics (BCLI) vs. Palatin Technologies (PTN) Head to Head Review
www.americanbankingnews.com - September 21 at 4:26 PM
 Analysts Expect Brainstorm Cell Therapeutics Inc. (BCLI) Will Announce Earnings of -$0.10 Per Share Analysts Expect Brainstorm Cell Therapeutics Inc. (BCLI) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - September 16 at 2:40 PM
Financial Survey: Sage Therapeutics (SAGE) and Brainstorm Cell Therapeutics (BCLI)Financial Survey: Sage Therapeutics (SAGE) and Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - September 13 at 10:16 AM
Head to Head Review: Brainstorm Cell Therapeutics (BCLI) & Esperion Therapeutics (ESPR)Head to Head Review: Brainstorm Cell Therapeutics (BCLI) & Esperion Therapeutics (ESPR)
www.americanbankingnews.com - September 12 at 10:24 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Director Irit Arbel Purchases 2,500 SharesBrainstorm Cell Therapeutics Inc. (BCLI) Director Irit Arbel Purchases 2,500 Shares
www.americanbankingnews.com - August 31 at 8:00 PM
BCLI: Phase 3 Trial of NurOwn® to Initiate SoonBCLI: Phase 3 Trial of NurOwn® to Initiate Soon
finance.yahoo.com - August 23 at 4:34 PM
BrainStorm Cell Therapeutics (BCLI) CEO Chaim Lebovits on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaBrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 17 at 10:52 PM
Maxim Group Analysts Give Brainstorm Cell Therapeutics Inc. (BCLI) a $9.00 Price TargetMaxim Group Analysts Give Brainstorm Cell Therapeutics Inc. (BCLI) a $9.00 Price Target
www.americanbankingnews.com - August 17 at 10:06 AM
Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings CallInvestor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - August 16 at 4:59 PM
Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc. (BCLI)
finance.yahoo.com - August 15 at 10:24 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Issues  Earnings ResultsBrainstorm Cell Therapeutics Inc. (BCLI) Issues Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
BrainStorm Cell Therapeutics Q2 Net Loss Widens - Quick FactsBrainStorm Cell Therapeutics Q2 Net Loss Widens - Quick Facts
www.rttnews.com - August 15 at 2:55 AM
BrainStorm Announces Second Quarter 2017 Financial Results - PR Newswire (press release)BrainStorm Announces Second Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - August 14 at 9:52 PM
BrainStorm Announces Second Quarter 2017 Financial ResultsBrainStorm Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 4:51 PM
Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16
finance.yahoo.com - August 10 at 5:39 PM
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy ... - PR Newswire (press release)BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy ... - PR Newswire (press release)
www.prnewswire.com - August 7 at 3:54 PM
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government AffairsBrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
finance.yahoo.com - August 7 at 3:53 PM
Brainstorm Cell Therapeutics Inc. (BCLI) to Release Earnings on WednesdayBrainstorm Cell Therapeutics Inc. (BCLI) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:20 AM
Compugen (CGEN) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head ContrastCompugen (CGEN) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head Contrast
www.americanbankingnews.com - July 30 at 7:43 AM
Brainstorm Cell Therapeutics (BCLI) Agrees with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn in ALSBrainstorm Cell Therapeutics (BCLI) Agrees with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn in ALS
www.streetinsider.com - July 26 at 2:30 AM
Brainstorm Cell Therapeutics (BCLI) Agrees with University of California Irvine Medical Center to Participate in ... - StreetInsider.comBrainstorm Cell Therapeutics (BCLI) Agrees with University of California Irvine Medical Center to Participate in ... - StreetInsider.com
www.streetinsider.com - July 25 at 4:19 PM
BCLI: Receives $16 Million Grant From CIRM to Fund Phase 3 Trial in ALSBCLI: Receives $16 Million Grant From CIRM to Fund Phase 3 Trial in ALS
finance.yahoo.com - July 25 at 4:19 PM
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALSBrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
finance.yahoo.com - July 25 at 4:19 PM
Brainstorm Cell Therapeutics Inc. (BCLI) Given a $8.00 Price Target by Maxim Group AnalystsBrainstorm Cell Therapeutics Inc. (BCLI) Given a $8.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - July 23 at 10:02 PM
Brainstorm Cell Storms Higher on Grant - Baystreet.caBrainstorm Cell Storms Higher on Grant - Baystreet.ca
www.baystreet.ca - July 22 at 4:22 PM
BUZZ-U.S. STOCKS ON THE MOVE-GE, Autoliv, EBay, Seacor ... - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-GE, Autoliv, EBay, Seacor ... - Nasdaq
www.nasdaq.com - July 21 at 6:00 PM
Mid-Morning Market Update: Markets Open Lower; General Electric ... - BenzingaMid-Morning Market Update: Markets Open Lower; General Electric ... - Benzinga
www.benzinga.com - July 21 at 6:00 PM

Social Media

Financials

Chart

Brainstorm Cell Therapeutics (NASDAQ BCLI) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.